Key Points
- A Taiwanese patient in his 50s lost vision in both eyes after taking Ozempic for four months and has filed the region's first official drug relief petition for permanent blindness.
- The case is generating significant public alarm as GLP-1 weight-loss medications surge in popularity throughout Asia and worldwide amid mounting concerns over rare side effects like eye strokes.
- Originally created for type 2 diabetes management, GLP-1 injections now face heightened international scrutiny and regulatory warnings regarding potential risks of non-arteritic anterior ischemic opti
Summary A dramatic case involving GLP-1 weight-loss injections has captured international attention after a Taiwanese man filed for government compensation, claiming the medication left him functionally blind in one eye and severely visually impaired in the other.
According to medical reports shared by Dr. Su Yi-feng from the Taipei City Hospital Union Branch, the patient, a man in his 50s suffering from chronic obstructive pulmonary disease (COPD) with a BMI of 32, was prescribed the popular GLP-1 receptor agonist Ozempic. Over four months of treatment, the patient successfully shed 10 kilograms without apparent adverse effects. However, on February 27, he awoke to sudden darkness in his right eye, while the visual acuity in his left eye plunged dramatically to 0.1.
Emergency department physicians diagnosed the patient with non-arteritic anterior ischemic optic neuropathy (NAION), an acute condition frequently described as an "eye stroke." NAION represents one of the leading causes of optic nerve-related blindness second only to glaucoma, occurring when restricted blood circulation permanently damages the optic nerve. Six months after the incident, the patient has shown no recovery, prompting the physician and patient to formally petition Taiwan's Food and Drug Administration (TFDA) and the Drug Relief Foundation for drug injury compensation.
While health authorities emphasize that an official causal link has not yet been verified—requesting comprehensive prescribing records and dosage timelines from the clinic—the revelation has intensified widespread scrutiny over GLP-1 drugs. Taiwan's TFDA confirmed that among 314 suspected adverse reaction reports filed for GLP-1 class medications, 12 involved ophthalmic complications, with this being the first claim filed specifically for irreversible blindness.
Originally developed to manage type 2 diabetes, GLP-1 formulations like semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (Mounjaro, Zepbound) have experienced an unprecedented global boom driven by social media trends and off-label aesthetic slimming use. In East Asian markets, where intense societal beauty standards place immense pressure on body management and rapid weight reduction, demand for these "miracle slimming shots" has exploded. However, growing medical alarms and subsequent regulatory actions—including recent U.S. FDA directives mandating explicit vision-loss warning labels—serve as a stark cautionary tale for consumers chasing effortless weight loss without fully weighing potential systemic risks.
Sponsored · Ad